Candel Therapeutics, Inc.

CADL

US1374041093

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 16/07/2024 BST			5-day change	1st Jan Change
7.29 ^USD	+10.12%		+23.14%	+395.92%

07-01	Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell Small Cap Completeness Index	CI
07-01	Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index	CI

Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 3000E Growth Index

July 30, 2024

Latest news about Candel Therapeutics, Inc.

Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell Small Cap Completeness Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell Microcap Value Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) dropped from Russell 3000E Value Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell Microcap Growth Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2000 Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 3000E Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2500 Growth Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 3000E Growth Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 3000 Growth Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2000 Growth Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2000 Dynamic Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell Small Cap Comp Growth Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 2500 Index	06-30	CI
Candel Therapeutics, Inc.(NasdaqGM:CADL) added to Russell 3000 Index	06-30	CI
FDA Grants Candel Therapeutics' CAN-3110 Orphan Drug Designation to Treat Recurrent High-Grade Glioma	05-30	MT
Candel Therapeutics Gets FDA's Orphan-Drug Status for Glioma Treatment	05-30	DJ
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting	05-23	CI
Candel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Sector Update: Health Care Stocks Decline Thursday Afternoon	04-11	MT
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug	04-11	MT
Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation	04-11	DJ
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors	04-09	CI
March Jobs Growth Exceed Expectations, Lifting US Equity Futures Pre-Bell	04-05	MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday	04-05	MT
Jobs Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday	04-05	MT

Chart Candel Therapeutics, Inc.

Duration

Period

More charts

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The Company has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform and is in ongoing clinical trials in non-small cell lung cancer (NSCLC), borderline resectable pancreatic cancer, and localized, non-metastatic prostate cancer. CAN-3110 is the lead product candidate from the HSV platform and is in an ongoing investigator-sponsored phase I clinical trial in recurrent high-grade glioma (HGG). Its enLIGHTEN Discovery Platform leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.

Sector

Biotechnology & Medical Research

Calendar

03/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

7.29 USD

Average target price

11 USD

Spread / Average Target

+50.89%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CANDEL THERAPEUTICS, INC.	+395.92%	197M
MODERNA, INC.	+25.83%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.69%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+30.52%	32.4B
ICON PUBLIC LIMITED COMPANY	+22.30%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.25%	14.52B
MEDPACE HOLDINGS, INC.	+49.18%	13.74B
BIO-TECHNE CORPORATION	+3.45%	12.17B

Other Biotechnology & Medical Research